BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07), Briefing.com reports. The business had revenue of $117.10 million for the quarter, compared to analysts' expectations of $113.99 million. During the same period in the prior year, the business earned ($0.19) earnings per share. The company's revenue for the quarter was up 35.1% compared to the same quarter last year.

BioCryst Pharmaceuticals Stock Down 4.0 %

Shares of BioCryst Pharmaceuticals stock traded down $0.29 during mid-day trading on Tuesday, reaching $7.06. 4,086,696 shares of the stock traded hands, compared to its average volume of 2,979,537. The business has a 50-day moving average of $7.84 and a 200 day moving average of $6.95. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The stock has a market capitalization of $1.46 billion, a PE ratio of -11.87 and a beta of 1.89.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, Needham & Company LLC restated a "buy" rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.